Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Dermatología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus. DUALTM IX - Add-on to SGLT2i
INTERVENTIONAL
Inicio: 23 de may de 2016
ID: NCT02773368
Completado
Fase 4
ClinicalTrials.gov
An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months
INTERVENTIONAL
Inicio: 1 de sept de 2007
ID: NCT00555061
Completado
ClinicalTrials.gov
Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population
OBSERVATIONAL
Inicio: 1 de jun de 2012
ID: NCT01598779
Completado
Fase 3
ClinicalTrials.gov
A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS
INTERVENTIONAL
Inicio: 11 de jun de 2018
ID: NCT03627767
Por invitación
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
INTERVENTIONAL
Inicio: 9 de mar de 2023
ID: NCT05735483
Activo, no recluta
ClinicalTrials.gov
The Role of Confocal Microscopy in Estimating Dupilumab Treatment Response for Moderate/Severe Atopic Dermatitis
OBSERVATIONAL
Inicio: 24 de abr de 2024
ID: NCT07098000
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis
INTERVENTIONAL
Inicio: 22 de sept de 2025
ID: NCT07116967
Por invitación
Fase 3
ClinicalTrials.gov
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
INTERVENTIONAL
Inicio: 12 de sept de 2023
ID: NCT05979441
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Dermatomyositis
INTERVENTIONAL
Inicio: 31 de oct de 2022
ID: NCT05437263
Completado
ClinicalTrials.gov
Longitudinal Study of Music Therapy's Effectiveness for Premature Infants and Their Caregivers: International Randomized Trial
INTERVENTIONAL
Inicio: 25 de ago de 2018
ID: NCT03564184
Por invitación
Fase 3
ClinicalTrials.gov
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants of Previous Amlitelimab Clinical Trials in Moderate to Severe Atopic Dermatitis.
INTERVENTIONAL
Inicio: 22 de ago de 2022
ID: NCT05492578
Desconocido
Fase 3
ClinicalTrials.gov
Immunotherapy of Colon Cancer With Autologous Perchloric Soluble Tumors Extracts
INTERVENTIONAL
Inicio: 1 de abr de 1971
ID: NCT00002455
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE)
INTERVENTIONAL
Inicio: 9 de oct de 2018
ID: NCT03622593
Terminado
Fase 4
ClinicalTrials.gov
A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Non-Pustular PalmoPlantar and Genital Psoriasis (Psoriatyk Special Sites)
INTERVENTIONAL
Inicio: 9 de oct de 2023
ID: NCT06042920
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma
INTERVENTIONAL
Inicio: 16 de ene de 2023
ID: NCT05608291
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
INTERVENTIONAL
Inicio: 1 de nov de 2010
ID: NCT01241591
Completado
ClinicalTrials.gov
A Randomized, Prospective, Parallel Group Study Comparing the Harmonic™ to Electrocautery in Abdominoplasties
INTERVENTIONAL
Inicio: 1 de oct de 2006
ID: NCT00506740
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib
INTERVENTIONAL
Inicio: 16 de feb de 2024
ID: NCT06120140
Completado
Fase 3
ClinicalTrials.gov
Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes
INTERVENTIONAL
Inicio: 1 de may de 2006
ID: NCT00318461
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
INTERVENTIONAL
Inicio: 1 de feb de 2024
ID: NCT06143878
Anterior
1
...
9
10
11
...
434
Siguiente
Filtros